Shire Q2 profit, sales up on drug product sales
11:08 EDT 1 Aug 2012 | Proactive Investors
Biopharmaceutical firm Shire (NASDAQ:SHPG) said second-quarter profits and sales climbed on increased market share in the U.S. and increased revenue for its attention deficit drug. The specialty drug company, which focuses on attention deficit and hy..
Original Article: Shire Q2 profit, sales up on drug product sales
More From BioPortfolio on "Shire Q2 profit, sales up on drug product sales"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
